<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04773483</url>
  </required_header>
  <id_info>
    <org_study_id>201021-B-02 Wall</org_study_id>
    <nct_id>NCT04773483</nct_id>
  </id_info>
  <brief_title>Quorn in Community Health Experiment</brief_title>
  <acronym>QUICHE</acronym>
  <official_title>Quorn in Community Health Experiment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Exeter</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Marlow Foods Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NIHR Exeter Clinical Research Facility</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Exeter</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In overweight individuals (BMI &gt; 27.5 kg/m2), does daily consumption of mycoprotein&#xD;
      containing Quorn Food products lower blood cholesterol compared with daily meat/fish&#xD;
      consumption?&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 9, 2020</start_date>
  <completion_date type="Anticipated">November 9, 2030</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postabsorptive blood cholesterol (free, total, LDL, HDL) concentrations</measure>
    <time_frame>4 weeks</time_frame>
    <description>Test for intervention vs control differences in postabsorptive blood cholesterol levels (mMol) pre and post intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postprandial blood cholesterol concentration</measure>
    <time_frame>3 hours</time_frame>
    <description>Test for intervention vs control differences in postprandial blood cholesterol levels (mMol) pre and post intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fingerprick blood glucose concentration</measure>
    <time_frame>4 weeks</time_frame>
    <description>Test for intervention vs control differences in blood glucose concentration (mMol) in postabsorptive and postprandial state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satiety</measure>
    <time_frame>4 weeks</time_frame>
    <description>Test for intervention vs control differences in satiety using a 10 centimetre 'Satiety Visual Analogue Scale' ratings, anchored by minimum to maximum response for a given aspect of satiety, where 0 cm is minimum and 10 cm is maximum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hedonic visual analogue scale</measure>
    <time_frame>4 weeks</time_frame>
    <description>Test for intervention vs control differences and changes in hedonic response using 10 cm 'Hedonic Visual Analogue Scale' ratings, anchored by minimum to maximum response for a given aspect of hedonic response, where 0 cm is minimum and 10 cm is maximum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal side-effects</measure>
    <time_frame>Once weekly, over 4 weeks</time_frame>
    <description>Test for intervention vs control differences in tolerance of diet</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fingerprick blood c-peptide</measure>
    <time_frame>4 weeks</time_frame>
    <description>Test for intervention vs control differences in C-peptide concentration (ng/ml) in postabsorptive and postprandial state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fingerprick blood triglyceride concentration</measure>
    <time_frame>4 weeks</time_frame>
    <description>Test for intervention vs control differences in blood triglyceride concentration (mMol) in postabsorptive and postprandial state</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Overweight and Obesity</condition>
  <arm_group>
    <arm_group_label>Quorn Food products</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Meat/fish products</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Quorn Foods products</intervention_name>
    <description>180 g mycoprotein (wet weight; corresponding to 45 g dry weight) per day (equates to approx. 215 g Quorn Foods products, depending on the product)</description>
    <arm_group_label>Quorn Food products</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Meat/fish products</intervention_name>
    <description>Standard meat/fish products matched to Quorn group for protein intake</description>
    <arm_group_label>Meat/fish products</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-70 years old&#xD;
&#xD;
          -  BMI &gt;27.5 kg/m2&#xD;
&#xD;
          -  Non allergic to penicillin/mycoprotein&#xD;
&#xD;
          -  Moderate levels of physical activity or below (self-identified; NDNS servey)&#xD;
&#xD;
          -  Omnivores&#xD;
&#xD;
          -  Not currently using cholesterol lowering medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt;18 or &gt;70 years old&#xD;
&#xD;
          -  BMI &lt;27.5 kg/m2&#xD;
&#xD;
          -  Allergies to penicillin/mycoprotein&#xD;
&#xD;
          -  Heavy exercisers (self idenfiied)&#xD;
&#xD;
          -  Vegetarian/vegans&#xD;
&#xD;
          -  Currently using cholesterol lowering medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin T Wall, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Exeter</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>George F Pavis, PhD</last_name>
    <phone>+44 (0) 1392 725906</phone>
    <email>g.pavis@exeter.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Raquel Revuelta Iniesta, PhD</last_name>
    <phone>+44 (0) 1392 724928</phone>
    <email>r.revuelta-iniesta@exeter.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Exeter</name>
      <address>
        <city>Exeter</city>
        <state>Devon</state>
        <zip>EX1 2LU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George F Pavis</last_name>
      <phone>01392 725906</phone>
      <email>g.pavis@exeter.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 22, 2021</study_first_submitted>
  <study_first_submitted_qc>February 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2021</study_first_posted>
  <last_update_submitted>June 16, 2021</last_update_submitted>
  <last_update_submitted_qc>June 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

